Thursday, October 8, 2026
Via News Knowledge File

AT&T Inc.

organization80% conf.·synced Aug 13, 2026

Telecommunications company providing wireless, fiber, and broadband services

52
sourced metrics
242
relationships
20
stated objectives
1
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Pe Ratio
8ratio
Jul 24, 2026source
52 Week High
29.79USD
Jul 24, 2026source
Stock Price
24.13USD
Jul 24, 2026source
Eps
0.65USD_per_share
Jul 22, 2026source
Shares Outstanding
6.9billions
Jul 22, 2026source
Fiber Customers Added
367000customers
Jul 22, 2026source
Internet Customers Added
646000customers
Jul 22, 2026source
Annual Dividend Per Share
1.11USD
Jul 22, 2026source
Fiber Locations Passed
38.6millions
Jul 22, 2026source
Diluted Eps Continuing Ops
0.66USD_per_share
Jul 22, 2026source
Fixed Wireless Customers Added
279000customers
Jul 22, 2026source
Adjusted Ebitda Margin
39.1percent
Jul 22, 2026source
Planned Shareholder Returns Total
18USD
Jul 22, 2026source
Annual Dividend Total
7.6USD
Jul 22, 2026source
Free Cash Flow
4.7USD
Jul 22, 2026source
Copper Service Penetration
3percent
May 20, 2026source
Debt
173.99USD
May 20, 2026source
Analyst Target Price
30.37USD
May 20, 2026source

Stated objectives

Free cash flow target for 2026

source
target: $18B+ by 2026-01-01 00:00:00stated

Adjusted EBITDA growth target for 2026

source
target: 3-4% by 2026-01-01 00:00:00stated

Share repurchase target for 2026

source
target: $8B by 2026-01-01 00:00:00stated

Adjusted EBITDA annual growth target by 2028

source
target: 5%+ by 2028-01-01 00:00:00stated

Adjusted EPS 3-year CAGR target through 2028

source
target: double-digit by 2028-01-01 00:00:00stated

Free cash flow growth target for 2027

source
target: +$1B by 2027-01-01 00:00:00stated

Free cash flow growth target for 2028

source
target: +$2B by 2028-01-01 00:00:00stated

Annual cost savings target by 2028

source
target: $4B+ by 2028-01-01 00:00:00stated

Total shareholder returns target for 2026-2028

source
target: $45B+ (30% of market cap, 75%+ of expected FCF) by 2028-01-01 00:00:00stated

Net debt to EBITDA ratio target after acquisitions close

source
target: ~3.2x immediately, ~3.0x by year-end 2026, return to 2.5x ra by 2029-01-01 00:00:00stated

Relationship graph · 242 connections

Competes with
62
Covered by
25
Customer of
19
Supplies to
18
acquired by
17
Employs
11
Developed by
10
Built on
9

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com